Business
Leading Healthcare Company, Fresenius Kabi, Selects Kneat's eValidation Platform
Leading Healthcare Company, Fresenius Kabi, Selects Kneat's eValidation Platform Canada...
About this update from Kneat.com, Inc.
[{"type":"text","content":"\n \n \n \n Leading Healthcare Company, Fresenius Kabi, Selects Kneat's eValidation Platform\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n In addition, another one of Kneat's largest pharmaceutical customers\n \n \n signs to transition from Kneat on-premise to Kneat SaaS\n \n \n \n \n LIMERICK,\n \n Ireland\n \n \n ,\n \n \n Jan. 26, 2023\n \n \n /CNW/ -\n \n kneat.com, inc.\n \n (TSX: KSI) (OTC: KSIOF)\n \n (\"Kneat\"\n \n or\n \n \"the Company\")\n \n , a leader in digitizing and automating validation and quality processes, is pleased to announce it has signed a three-year SaaS Master Services Agreement (\n \n \"the Agreement\"\n \n ) with Fresenius Kabi Germany, a leading supplier of clinical nutrition, infusions, pharmaceuticals and medical technology. The agreement is effective immediately and allows the company to scale Kneat across all its business divisions and affiliates.\n \n \n \n \n \n \n \n \n \n With more than 3,500 branded products, and its own logistics and decentralized supply centers, Fresenius Kabi continuously improves its processes to supply clinics, pharmacies, medical practices, dealers, care facilities and patients at home with trusted therapies. By deploying Kneat's offering to digitize the validation of its production equipment, facilities and utilities, Fresenius Kabi continues its path to even greater operational efficiencies and data integrity for these validation processes.\n \n \n This Agreement marks Kneat's first engagement with Fresenius Kabi, which employs more than 41,000 people worldwide. Fresenius Kabi is an independent subsidiary of Fresenius, a more than 300,000-employee global healthcare group. Kneat's demonstrated track record of delivering a strong ROI to its life sciences customers positions Kneat to scale to multiple manufacturing sites and processes across Fresenius Kabi. The initial deployment is across five sites for validating production equipment, facilities and utilities.\n \n \n Implementation will commence in Q1 2023, with an expected go-li...